GFAP and chronic kidney disease: While plasma p‐tau231, GFAP, and NfL were robust predictors of clinical (and especially longitudinal) outcomes, the predictive accuracy of these biomarkers was modified in many cases by higher eGFR levels such that associations were stronger in individuals with better kidney function (stage 0–2 CKD) and no longer present in individuals with stage 3 CKD.